Sanegene Bio

SanegeneBio is a rapidly growing biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. Founded in 2021, SanegeneBio leverages cutting-edge delivery technology and has established proprietary chemical modification platforms. The company has built a robust portfolio of RNAi therapeutics for a range of therapeutic areas including cardiovascular and metabolic diseases, immunology-related diseases, and nervous system diseases. They are committed to developing innovative RNAi medicines to address unmet medical needs worldwide.

SanegeneBio has achieved significant milestones in its short existence. Their first siRNA drug, SGB-3403, targeting PCSK9 for the treatment of hypercholesterolemia, has entered into clinical trials in both China and Australia. The company has also secured significant funding through several rounds of financing, led by investors such as Tencent Investment and Yuanbio Venture Capital. With a strong foundation in RNAi drug discovery and a focus on innovation, SanegeneBio is well-positioned to become a leading player in the field of RNAi therapeutics.

SanegeneBio is a rising RNAi-based company committed to developing innovative RNA interference therapeutics that will reshape patients' lives and address unmet medical needs globally. Driven by cutting-edge delivery technology, SanegeneBio is dedicated to creating transformational RNAi medicines through scientific innovation and a commitment to serving patients in need worldwide.

Sanegene Bio fosters a culture of innovation and teamwork, valuing quick development in a fast-growing career path. They emphasize the importance of realizing the full potential of RNAi technology and bringing life-changing RNA medicines to reality, with a vision of becoming a world-class RNAi biopharmaceutical innovator serving patients in need worldwide.

SanegeneBio prioritizes building a diverse and inclusive workplace where every employee feels valued, respected, and empowered to contribute their unique talents. They foster a culture of inclusivity through a variety of initiatives, such as recruiting and retaining a diverse workforce, creating a supportive environment for all employees, and promoting equal opportunities for advancement. By valuing the perspectives and experiences of all individuals, SanegeneBio aims to build a more equitable and innovative workplace, ensuring that all voices are heard and that all employees have the opportunity to thrive.